OnaBotulinumtoxin-A in Chronic Migraine Patients with Short or Long Disease History (the BACH Study)
OnaBotulinumtoxin-A Effectiveness Evaluation in Chronic Migraine Patients with Short or Long Disease History: an Italian Multicentric Study (the BACH Study)
About This Trial
The goal of this observational prospective multicentric study, 12 months duration is to investigate whether the history of Chronic Migraine and, more precisely, its duration for over or less than 10 years, can predict OBT-A treatment effectiveness. Since CM patients may have a complex psychopathological profile and psychiatric symptoms represent a bad prognostic factor influencing treatment effectiveness, the present study will also aim at evaluating if the psychopathological profile of the enrolled patients may influence the outcome.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
OnabotulinumtoxinA OBT-A
Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.